A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease

2025-523515-11-00 Protocol DNLI-K-0001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 3 Apr 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 3 sites · Protocol DNLI-K-0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 68
Countries 1
Sites 3

Early Alzheimer's Disease

Key facts

Sponsor
Denali Therapeutics Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
3 Apr 2026 → ongoing
Decision date (initial)
2026-02-18
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Early Alzheimer's Disease

VersionLevelCodeTermSystem organ class
20.0 LLT 10001896 Alzheimer's disease 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Denali Therapeutics Inc.

Sponsor organisation
Denali Therapeutics Inc.
Address
161 Oyster Point Boulevard
City
South San Francisco
Postcode
94080-2042
Country
United States

Scientific contact point

Organisation
Denali Therapeutics Inc.
Contact name
Richard Tsai, MD

Public contact point

Organisation
Denali Therapeutics Inc.
Contact name
Clinical Trials Group

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 27 3
Rest of world
United Kingdom
41

Investigational sites

Netherlands

3 sites · Ongoing, recruiting
Brain Research Center Den Bosch B.V.
Neurology, Statenlaan 37, 5223 LA, 's-Hertogenbosch
Brain Research Center Amsterdam B.V.
Neurology, Cronenburg 2, 1081 GN, Amsterdam
Brain Research Center Zwolle B.V.
Neurology, Dokter Stolteweg 90, 8025 AZ, Zwolle

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-04-03 2026-05-27

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-13 Netherlands Acceptable
2026-02-16
2026-02-18